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Purpose/Objective: To compare dose sparing to stomach, duodenum 
and small bowel using radiobiological endpoints for 3D and intensity-
modulated arctherapy (IMAT) plans for locally advanced pancreatic 
cancer (LAPC). 
Materials and Methods: For 11 patients treated with chemo-
radiotherapy, the original 3D conformal treatment plan (50.4 Gy / 28 
fr to the tumour and elective nodes, PTV5040, then 9 Gy / 5 fr to the 
primary tumour, PTV5940) was compared retrospectively to an IMAT 
plan with a simultaneous integrated boost(59.4 Gy (PTV5940) and 52 
Gy (PTV5040) in 33 fractions). In both techniques, target coverage 
(D99% >95% prescribed dose) and dose constraints to critical organs 
(cord Dmax< 40 Gy, liver D50% <20 Gy and kidneys, R kidney D50%< 20 Gy, 
L kidney D30% < 20 Gy) were strictly respected. Plans were compared 
using the PTV conformity index CI95% and dose metrics of gastro-
intestinal (GI) organs (stomach: V50 and Dmax to 2cc, combined stomach 
and duodenum (StoDuo): V50 and small bowel: V45). NTCP modelling of 
stomach, duodenum and small bowel was used to rank plans by 
estimating GI toxicity, using the full range of NTCP parameter values 
for these organs found in the literature. 
Results: Improved dose sparing of critical organs for all 11 patients 
was observed with the IMAT technique, due to higher dose 
conformation of the target volume: IMAT mean PTV5940 CI95%= 1.08 ± 
0.03 vs 3D mean PTV5940 CI95% = 1.83 ± 0.25, p<0.001. In particular, 
dose constraints for L kidney were met for 11/11 patients for IMAT 
and only 6/11 for 3D. A reduction in acute toxicity of small bowel may 
be possible using IMAT due to the reduction of the V45 volume (IMAT 
mean 285.1 ±124.1 cm3 vs 3D mean 348.8±147.3 cm3, p<0.001). A 
similar reduction in high dose was seen for StoDuo when using IMAT: 
StoDuo V50 (IMAT mean 26.4±5.8 cm3 vs 3D mean 33.7±8.1 cm3 
p<0.0001). For stomach, although there was no significant difference 
in the two techniques for the Stomach Dmax (3D mean = 59.7±2.6 Gy 
and IMAT mean= 58.3±3.6 Gy), a reduction in the Stomach V50 volume 
was observed with IMAT (IMAT mean 18.7±12.3 cm3 vs 3D mean 
28.1±20.4 cm3, p=0.009). Using NTCP estimates of GI toxicity to rank 
plans showed that the IMAT technique was always preferable to 3D 
conformal therapy, independent of the values used in the 
radiobiological modelling.  
Conclusions: The predicted dose sparing obtained with the IMAT 
technique is particularly important in the context of concurrent 
chemo-radiotherapy for pancreatic cancer where GI toxicity is often a 
limiting factor. For stomach, duodenum and small bowel, NTCP 
analysis predicts a significant advantage in using IMAT. Using 
radiobiological endpoints presents a simple method for obtaining 
relative plan ranking, which is robust to the choice of values used in 
the NTCP modelling.  
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Purpose/Objective: Higher tumour stage is an independent predictor 
of local failure. We present a retrospective planning study to 
determine the feasibility of dose escalation in very advanced anal 
cancers using a simultaneous integrated boost (SIB) with a small bowel 
dose constraint of V30Gy≤300cc (Devisetty et al 2009).  
Materials and Methods: Five consecutive CT datasets of patients with 
stage T3N2-T4N3 anal canal were identified. Planning target volume 1 
(PTV1) included tumour and pelvic elective nodal areas; PTV2 
included primary tumour and involved nodes. Three types of IMRT 
plans were generated. The CLINICAL plan utilised a sequential phase1 
inverse-planned 7-field IMRT followed by either a conformal or 
inverse-planned phase 2. The SIB plans were prescribed 42Gy in 
1.5Gy/fraction to PTV 1 and 50.4Gy (SIB1.8) and 56Gy (SIB2.0) to PTV2 
respectively. Prescription dose to the CLINICAL plan was 30.6Gy and 
19.8Gy in 1.8Gy/fractions to PTV1 and PTV2 respectively. The plans 
were optimised to meet small bowel, genitalia, bladder and femoral 
head constraints. Patients were previously treated with the CLINICAL 
plan and did not experience high grade acute bowel toxicity. 
Maintaining the same risk of gastro-intestinal toxicity as achieved in 
the CLINICAL plan was a priority. The CLINICAL plan was used as the 
reference and the small bowel dose constraint V30Gy≤300cc was aimed 
for in the SIB plans. Small bowel V30Gy and coverage of PTV2 by 95% 
prescription isodose and conformity index (CI) were compared.  
Results: All plans achieved the minimum dose coverage of 95% 
prescription dose. No plan exceeded a maximum dose of 105% to 2% of 
the PTV volume. The SIB test arms had better conformity index (CI) 
than the clinical plan. 4/5 patients met the bowel dose constraint of 
V30Gy≤300cc. One case failed to achieve small bowel constraint as 
223cc bowel overlapped PTV. 
 









PTV D98% (Gy) 49.0 (48-49.4) 48.3 (47.9-48.5) 53.5 (53.5-53.9) 
PTV D2% (Gy) 51.9 (51.7-52.3) 52.3 (52.2-52.4) 58 (57.8-58.4) 
PTV D50% (Gy) 50.6 (50.4-50.7) 50.4 (50.4-50.5) 55.9 (55.9-56.1) 
PTV D95% (Gy) 49.3 (48.8-49.7) 48.7 (48.4-48.9) 54 (54-54.3) 
CI 1.40 1.15 1.15 
 
  
Conclusions: SIB IMRT is achievable whilst meeting the bowel 
constraint of V30Gy≤300cc providing that the physical volume of the 
bowel and PTV overlap is kept below 190cc. Acceptable small bowel 
dose increases are seen in the SIB plans compared to the clinical plan. 
Dose escalation is achievable for prescription doses of 50.4Gy and 
56Gy to the primary volume and plans for escalation to 64.4Gy are in 
progress. 
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Purpose/Objective: The accurate and fast dose calculation is an 
essential requirement of modern Radiotherapy (RT).The ability to 
predict dose with high accuracy is usually associated with the 
probabilistic Monte Carlo methods, but with long calculation times for 
use in daily clinical practice. The dose-calculation algorithms used in 
clinical practice, such as pencil-beam convolution and the 
convolution/superposition (method used in Anisotropic Analytical 
Algorithm - AAA) typically include models to significantly reduce the 
computation time (pre-calculated dose kernels in water with Monte 
Carlo), but with decreasing accuracy, especially in the presence of 
heterogeneities. The deterministic dose-calculation algorithm Acuros® 
XB for photons, which was recently implemented in the treatment 
planning system (TPS) Eclipse™ is able to fulfill these two 
